Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$6.37 - $15.23 $9.67 Million - $23.1 Million
-1,518,615 Reduced 58.41%
1,081,133 $16.4 Million
Q2 2022

Aug 12, 2022

SELL
$4.95 - $9.16 $845,974 - $1.57 Million
-170,904 Reduced 6.17%
2,599,748 $19.5 Million
Q1 2022

May 16, 2022

BUY
$5.64 - $9.8 $2.35 Million - $4.08 Million
416,759 Added 17.71%
2,770,652 $25.2 Million
Q4 2021

Feb 08, 2022

SELL
$7.02 - $13.33 $1.92 Million - $3.66 Million
-274,204 Reduced 10.43%
2,353,893 $16.5 Million
Q3 2021

Nov 15, 2021

BUY
$11.32 - $16.63 $24,790 - $36,419
2,190 Added 0.08%
2,628,097 $30 Million
Q2 2021

Sep 13, 2021

BUY
$15.16 - $18.97 $39.8 Million - $49.8 Million
2,625,907 New
2,625,907 $42 Million

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.